Balyasny Asset Management LLC Keros Therapeutics, Inc. Transaction History
Balyasny Asset Management LLC
- $58 Billion
- Q3 2024
A detailed history of Balyasny Asset Management LLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 325,434 shares of KROS stock, worth $17.6 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
325,434
Previous 88,636
267.16%
Holding current value
$17.6 Million
Previous $4.05 Million
366.59%
% of portfolio
0.03%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding KROS
# of Institutions
174Shares Held
30.3MCall Options Held
76.8KPut Options Held
9K-
Black Rock Inc. New York, NY2.51MShares$136 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.9MShares$103 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.86MShares$101 Million0.0% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.52MShares$82.5 Million7.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.51MShares$82 Million0.01% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $1.39B
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...